156 related articles for article (PubMed ID: 27055943)
21. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
22. The influence of the ethane-1,2-diamine ligand on the activity of a monofunctional platinum complex.
Graziotto ME; Akerfeldt MC; Gunn AP; Yang K; Somerville MV; Coleman NV; Roberts BR; Hambley TW; New EJ
J Inorg Biochem; 2017 Dec; 177():328-334. PubMed ID: 28789807
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia Active Platinum(IV) Prodrugs of Orotic Acid Selective to Liver Cancer Cells.
Maji M; Bhattacharya I; Acharya S; Chakraborty MP; Gupta A; Mukherjee A
Inorg Chem; 2021 Apr; 60(7):4342-4346. PubMed ID: 33711231
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17217-17227. PubMed ID: 31729519
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes.
Lorenzo J; Delgado A; Montaña ÁM; Mesas JM; Alegre MT; Rodríguez Mdel C; Avilés FX
Eur J Med Chem; 2014 Aug; 83():374-88. PubMed ID: 24980119
[TBL] [Abstract][Full Text] [Related]
26. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17228-17240. PubMed ID: 31728483
[TBL] [Abstract][Full Text] [Related]
28. Copper-free click-chemistry platform to functionalize cisplatin prodrugs.
Pathak RK; McNitt CD; Popik VV; Dhar S
Chemistry; 2014 Jun; 20(23):6861-5. PubMed ID: 24756923
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, characterization and cytotoxicity evaluation of some new platinum(II) complexes of tetrazolo[1,5-a]quinolines.
Bekhit AA; El-Sayed OA; Al-Allaf TA; Aboul-Enein HY; Kunhi M; Pulicat SM; Al-Hussain K; Al-Khodairy F; Arif J
Eur J Med Chem; 2004 Jun; 39(6):499-505. PubMed ID: 15183908
[TBL] [Abstract][Full Text] [Related]
30. On the stability and biological behavior of cyclometallated Pt(IV) complexes with halido and aryl ligands in the axial positions.
Escolà A; Crespo M; López C; Quirante J; Jayaraman A; Polat IH; Badía J; Baldomà L; Cascante M
Bioorg Med Chem; 2016 Nov; 24(22):5804-5815. PubMed ID: 27670096
[TBL] [Abstract][Full Text] [Related]
31. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
32. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
33. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
34. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
35. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
36. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
[TBL] [Abstract][Full Text] [Related]
37. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
38.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
40. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
